Sophiris Bio (SPHS) Stock Price, News & Analysis

Company Overview

Sophiris Bio, Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for urologic diseases and rare endocrine disorders. Founded in 2003 and headquartered in New York with research operations in Vancouver, Canada, the company applies precision medicine approaches to address unmet needs in prostate disease, male health and congenital endocrine conditions. Over the years, Sophiris Bio has strategically acquired complementary assets to expand its pipeline, rebranding after its merger with Nevan Pharmaceuticals in 2014 and strengthening its footprint across North America and Europe.

The company’s lead candidate, nevanimibe, is an oral inhibitor of acyl‐CoA:cholesterol acyltransferase 1 (ACAT1) that is currently being evaluated in Phase 2 clinical trials for congenital adrenal hyperplasia. In parallel, Sophiris maintains a portfolio of early‐stage programs targeting androgen receptor signaling and other pathways implicated in benign prostatic hyperplasia and prostate cancer. By leveraging proprietary delivery technologies and robust preclinical models, the company aims to advance differentiated small molecules through proof‐of‐concept studies and into pivotal development stages.

Under the leadership of President and Chief Executive Officer David Lee, Sophiris Bio is governed by a board of directors with extensive experience in drug development, regulatory affairs and commercialization. The executive team includes seasoned veterans from the biotechnology and pharmaceutical industries, complemented by a scientific advisory board drawn from leading academic institutions. Through collaborations with contract research organizations and strategic partnerships with academic centers, Sophiris Bio continues to build a pipeline designed to improve patient outcomes in both common and rare urologic and endocrine disorders.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $4 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SPHS Stock Analysis - Frequently Asked Questions

How were Sophiris Bio's earnings last quarter?

Sophiris Bio, Inc. (OTCMKTS:SPHS) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02.

How do I buy shares of Sophiris Bio?

Shares of SPHS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sophiris Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sophiris Bio investors own include Sarepta Therapeutics (SRPT), Intercept Pharmaceuticals (ICPT), (CPXX) (CPXX), SELLAS Life Sciences Group (SLS), Advanced Micro Devices (AMD), Rigel Pharmaceuticals (RIGL) and Anavex Life Sciences (AVXL).

Company Calendar

• Last Earnings: 5/09/2019
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:SPHS
• CIK: 1563855
• Web: www.sophirisbio.com
• Phone: (858) 777-1760
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,550,000
• Free Float: N/A
• Market Cap: $4 thousand
• Optionable: Not Optionable
• Beta: 1.94